Articles dans des revues avec comité de lecture (396)
  1. 217. Schmidt, M. L. M., Scheulen, M. E., Dittrich, C., Obrist, P., Marschner, N., Dirix, L. Y., Schmidt, M., Rüttinger, D., Schuler, M., Reinhardt, C., & Awada, A. (2010). An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer. Annals of oncology, 21(2), 275-282. doi:10.1093/annonc/mdp314
  2. 218. Awada, A., Lacombe, D., & Liberatoscioli, C. (2010). Design and performance of clinical trials in head and neck cancer. Current opinion in oncology, 22(3), 184-185. doi:10.1097/CCO.0b013e3283376aa8
  3. 219. Van Den Eynde, M., Awada, A., & Hendlisz, A. (2010). Is tailored adjuvant treatment for colon cancer possible? Clinical colorectal cancer, 9(1), 15-21. doi:10.3816/CCC.2010.n.002
  4. 220. Awada, A., Wildiers, H., & Cocquyt, V. (2010). Le régime TC dans les stades précoces de cancer du sein: Avantages, indications & perspectives. Belgian oncology news.
  5. 221. Dirix, L. Y., Awada, A., Bron, D., Canon, J.-L., De Greve, J., Humblet, Y., Peeters, M., Van Belle, S., Vansteenkiste, J., & Vermorken, J. B. (2010). Practice guidelines on the use of erythropoiesis-stimulating agents in the treatment of chemotherapy induced anemia. Belgian journal of medical oncology, 4(2), 57-64.
  6. 222. Awada, A., & Lacombe, D. (2010). Meeting report AACR-NCI-EORTC International conference (15-19 November 2009) on Molecular targets and cancer therapics. Expert review of anticancer therapy, 10(3), 319-320.
  7. 223. Ladjeroud, A., Awada, A., Bouzid, K., & Piccart-Gebhart, M. (2010). L’association hormonothérapie-thérapie ciblée dans le cancer du sein. Oncologie, 12(7), 422-431. doi:10.1007/s10269-010-1910-y
  8. 224. Gerlier, L., Lamotte, M., Awada, A., Bosly, A., Bries, G., Cocquyt, V., Focan, C., Henry, S., Lalami, Y., Machiels, J. P., Mebis, J., Straetmans, N., Verhoeven, D., & Somers, L. (2010). The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma. BMC cancer, 10, 642. doi:10.1186/1471-2407-10-642
  9. 225. Vereecken, P., Awada, A., Suciu, S., Castro, G., Morandini, R., Litynska, A., Lienard, D., Ezzedine, K. K., Ghanem, G. E., & Heenen, M. (2009). Evaluation of the prognostic significance of serum galectin-3 in American Joint Committee on Cancer stage III and stage IV melanoma patients. Melanoma research, 19(5), 316-320. doi:10.1097/CMR.0b013e32832ec001
  10. 226. Moulin, C., Metzger-Filho, O., & Awada, A. (2009). Changing the clinical picture of challenging tumors: tales becoming reality? Future oncology, 5(6), 785-802. doi:10.2217/fon.09.49
  11. 227. Hanauske, A.-R., Dumez, H., Piccart-Gebhart, M., Yilmaz, E., Graefe, T., Gil, T., Simms, L., Musib, L., & Awada, A. (2009). Pemetrexed combined with paclitaxel: a dose-finding study evaluating three schedules in solid tumors. Investigational new drugs, 27(4), 356-365. doi:10.1007/s10637-008-9193-5
  12. 228. Metzger-Filho, O., Moulin Correa, C., de Azambuja, E., & Awada, A. (2009). Larotaxel: Broadening the road with new taxanes. Expert opinion on investigational drugs, 18(8), 1183-1189. doi:10.1517/13543780903119167
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
    37     38 39 Suivant >>